  Current methods for capturing circulating tumor cells (CTCs) are based on the
overexpression of cytokeratin (CK) or epithelial cell-adhesion molecule (EpCAM)
on cancer cells. However, during the process of metastasis, tumor cells undergo
epithelial to mesenchymal transition (EMT) that can lead to the loss of
CK/EpCAM expression. Therefore, it is vital to develop a capturing technique
independent of CK/EpCAM expression on the cancer cell. To develop this
technique, it is important to identify common secondary oncogenic markers
overexpressed on tumor cells before and after EMT. We analyzed the biomarker
expression levels in tumor cells, before and after EMT, and found two common
proteins human epidermal growth factor receptor 2 (Her2) and epidermal growth
factor receptor (EGFR) whose levels remained unaffected. So, we synthesized
immunomagnetic iron nanocubes covalently conjugated with antibodies of Her2 or
EGFR to capture cancer cells irrespective of the EMT status. The nanocubes
showed high specificity (6 to 9 fold) in isolating the cancer cells of interest
from a mixture of cells spiked in serum. We characterized the captured cells
for identifying their EMT status. Thus, we believe the results presented here
would help in the development of novel strategies for capturing both primary
and metastatic cancer cells from patients blood to develop an effective
treatment plan.
